LY6D and colorectal carcinoma: The AtrxKO signature contained markers of squamous cells (LY6D, KRT5, KRT13, SPRR1A and TRIM29) and those associated with the basal–squamous pancreatic ductal adenocarcinoma subtype and/or metaplastic CRC (CAV1, AQP3, FAM83A, F3 and AQP5)24,25.